Joel Isaacson & Co., LLC Halozyme Therapeutics, Inc. Transaction History
Joel Isaacson & Co., LLC
- $2.39 Billion
- Q2 2025
A detailed history of Joel Isaacson & Co., LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Joel Isaacson & Co., LLC holds 10,247 shares of HALO stock, worth $681,118. This represents 0.02% of its overall portfolio holdings.
Number of Shares
10,247
Previous 10,247
-0.0%
Holding current value
$681,118
Previous $653,000
18.38%
% of portfolio
0.02%
Previous 0.03%
Shares
4 transactions
Others Institutions Holding HALO
# of Institutions
621Shares Held
127MCall Options Held
408KPut Options Held
388K-
Black Rock Inc. New York, NY17.6MShares$1.17 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.2MShares$814 Million0.01% of portfolio
-
State Street Corp Boston, MA5.94MShares$395 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA3.47MShares$230 Million0.03% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.4MShares$226 Million3.92% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $9.26B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...